Hepatitis B next great challenge: Arrowhead

1:11 PM ET Mon, 10 Nov 2014

Chris Anzalone, Arrowhead CEO, discusses current studies on the hepatitis B virus and its effect on the liver, and whether the company is gaining the confidence back of shareholders.